DUBLIN–(BUSINESS WIRE)–The “Global
Manufacturing and Supply Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics 2014-2019” report has been added to ResearchAndMarkets.com’s
offering.
This report provides details of the latest manufacturing and supply
agreements announced in the pharmaceutical, biotechnology, device and
diagnostic sectors. Fully revised and updated, the report provides
details of manufacturing and supply agreements from 2014 to 2019.
The report provides a detailed understanding and analysis of how and why
companies enter manufacturing and supply deals.
A supply or manufacturing agreement is normally between a product
manufacturer and product owner in which an owner outsources the
manufacture and supply of its product(s) to the service company in a
defined territory.
Manufacturing and supply agreements provide a popular method of
maximizing the value of a product launched into a market. The deals
allow the product marketer to focus on its sales and marketing efforts
whilst relying on a third party to manufacture and supply product on
demand, enabling rapid response to market demands. It also ensures that
the marketer does not need to invest in costly infrastructure and
expertise ahead of knowing whether the product will be successful or
sustainable.
Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
and databases do not.
This report contains a comprehensive listing of over 2,500 manufacturing
and supply deals announced since 2014 as recorded in the deals and
alliances database, including financial terms where available, plus
links to online copies of actual manufacturing and supply contract
documents as submitted to the Securities Exchange Commission by
companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner’s flexibility on a wide range of important issues,
many of which will have a significant impact on each party’s ability to
derive value from the deal.
The initial chapters of this report provide an orientation of
manufacturing and supply deal making and business activities. Chapter 1
provides an introduction to the report, whilst chapter 2 provides an
analysis of the trends in manufacturing and supply deal making as well
as a discussion on the merits of the type of deal.
Chapters 3 and 4 provide an overview of the structure of manufacturing
and supply deals. The chapter includes numerous case studies to enable
understanding of both pure manufacturing and supply deals and
multicomponent deals where manufacturing and supply forms a part.
Chapter 5 provides a review of the leading manufacturing and supply
deals since 2014. Deals are listed by headline value. Where the deal has
an agreement contract published at the SEC a link provides online access
to the contract via the deals and alliances database.
Chapter 6 provides a review of the top 50 most active biopharma
companies in manufacturing and supply. Where the deal has an agreement
contract published at the SEC a link provides online access to the
contract via the deals and alliances database.
Chapter 7 provides a comprehensive and detailed review of manufacturing
and supply deals signed and announced since 2014 where a contract
document is available. Each deal title links via Weblink to an online
version of the actual contract document, providing easy access to each
contract document on demand.
The report includes deals announced by hundreds of life science
companies including big pharma such as Abbott, Abbvie, Actavis, Amgen,
Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai,
Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan,
Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant,
amongst many others.
The report also includes numerous table and figures that illustrate the
trends and activities in manufacturing and supply deal making since 2014.
In addition, a comprehensive appendix is provided organized by
manufacturing and supply company A-Z, stage of development, therapeutic
target, technology type and deal type definitions. Each deal title links
via Weblink to an online version of the deal record and where available,
the contract document, providing easy access to each contract document
on demand.
In conclusion, this report provides everything a prospective dealmaker
needs to know about manufacturing and supply partnering in the research,
development and commercialization of technologies and products.
Key benefits
-
In-depth understanding of manufacturing and supply deal trends since
2014 -
Analysis of the structure of manufacturing and supply agreements with
numerous real life case studies -
Comprehensive access to over 2,500 actual manufacturing and supply
deals entered into by the world’s biopharma companies -
Detailed access to actual manufacturing and supply deals entered into
by the leading fifty bigpharma companies -
Comprehensive access to all manufacturing and supply deals entered
since 2014 -
Insight into the terms included in a manufacturing and supply
agreement, together with real world clause examples - Understand the key deal terms companies have agreed in previous deals
-
Undertake due diligence to assess suitability of your proposed deal
terms for partner companies
Report Scope
The report is intended to provide the reader with an in-depth
understanding of the manufacturing and supply trends and structure of
deals entered into by pharma, biotech, device and diagnostics companies
worldwide.
The report includes:
-
Trends in manufacturing and supply dealmaking in the biopharma
industry since 2014 - Analysis of manufacturing and supply deal structure
- Case studies of real-life manufacturing and supply deals
-
Access to over 2,500 manufacturing and supply deal records covering
pharma, biotech, devices and diagnostics since 2014 - The leading manufacturing and supply deals by value since 2014
- Most active manufacturing and supply dealmakers since 2014
- The leading manufacturing and supply partnering resources
In the report, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual
deal record, providing easy access to each contract document where
available.
The report provides comprehensive access to available records for over
2,500 manufacturing and supply deals, including contract documents where
available.
Analyzing actual contract agreements allows assessment of the
following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sub-licensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
-
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type? - Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Manufacturing and Supply Deal Making
Chapter 3 – Overview of Manufacturing and Supply Deal Structure
Chapter 4 – Overview of Supply Deal Structure
Chapter 5 – Leading Manufacturing and Supply Deals
Chapter 6 – Top 25 Most Active Manufacturing and Supply Dealmakers
Chapter 7 – Manufacturing and Supply Deals Contract Directory Since 2014
For more information about this report visit https://www.researchandmarkets.com/r/y991ks
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Pharmaceuticals,
Diagnostics